NEW CFO Wedgie breakEarnings TOMMOROW new CFO appointed worked with ATAI previously where he led a 225M initial public offering in 2021. Projections look good
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.62 USD
−88.45 M USD
426.00 K USD
70.48 M
About Altimmune, Inc.
Sector
Industry
CEO
Vipin K. Garg
Website
Headquarters
Gaithersburg
Founded
1997
FIGI
BBG000FXML90
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Wyckoff Bullish Patterns - Dollar getting stronger! Easy MoneyICEUS:DX1!
Dollar getting stronger on daily and weekly chart! Wyckoff Wave Indicator shows the power of buyers who are taking control.
How Wyckoff Wave Indicator works?
The Wyckoff Wave Indicator and the Weis Wave Indicator are both technical analysis tools derived from the principles of Rich
ALT | Heavy Accumulation in Progress | LONGAltimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed fo
ALT Altimmune Options Ahead of EarningsAnalyzing the options chain and the chart patterns of ALT Altimmune prior to the earnings report this week,
I would consider purchasing the 9usd strike price at the money Calls with
an expiration date of 2024-6-21,
for a premium of approximately $2.22.
If these options prove to be profitable prior t
ALT is a stockALT is a stock in the pharmaceutical and weight-loss drug sector.
It was recommended by a friend.It can be followed for the long term.
Weekly MACD has recently moved into a sell position.
It's not yet at the buying point.
There is a decrease in weekly and Monthly volüme.
Nice breakout from a falling wedge on $ALTBreakout from falling wedge at very high volume.
This is a GREEN ANT stock NASDAQ:ALT
long ALT Entry pointit might be ridiculous to say but if price were to fall back to 9-10 which even if it were too due to its massive runup in price. A retracement in current price action would only provide another opportunity long if one were to present itself. Currently the chart the left is the daily timeframe and
ALT Altimmune Options Ahead of EarningsAnalyzing the options chain and the chart patterns of ALT Altimmune prior to the earnings report this week,
I would consider purchasing the 3.00usd strike price Puts with
an expiration date of 2024-1-19,
for a premium of approximately $0.99.
If these options prove to be profitable prior to the earni
Altimmune , you better leave this sinking titanic Altimmune had a good run, but right now it's sinking faster than the Titanic. It breached both the 100 and 200 MA on H4 and is on its way down to around $5.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ALT is 9.49 USD — it has decreased by −4.30% in the past 24 hours. Watch Altimmune, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Altimmune, Inc. stocks are traded under the ticker ALT.
ALT stock has risen by 9.87% compared to the previous week, the month change is a 22.09% rise, over the last year Altimmune, Inc. has showed a 279.60% increase.
We've gathered analysts' opinions on Altimmune, Inc. future price: according to them, ALT price has a max estimate of 28.00 USD and a min estimate of 10.00 USD. Watch ALT chart and read a more detailed Altimmune, Inc. stock forecast: see what analysts think of Altimmune, Inc. and suggest that you do with its stocks.
ALT stock is 35.79% volatile and has beta coefficient of 3.07. Track Altimmune, Inc. stock price on the chart and check out the list of the most volatile stocks — is Altimmune, Inc. there?
Today Altimmune, Inc. has the market capitalization of 522.37 M, it has increased by 13.11% over the last week.
Yes, you can track Altimmune, Inc. financials in yearly and quarterly reports right on TradingView.
Altimmune, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ALT earnings for the last quarter are −0.32 USD per share, whereas the estimation was −0.36 USD resulting in a 10.26% surprise. The estimated earnings for the next quarter are −0.35 USD per share. See more details about Altimmune, Inc. earnings.
Altimmune, Inc. revenue for the last quarter amounts to 5.00 K USD, despite the estimated figure of 714.00 USD. In the next quarter, revenue is expected to reach 833.00 USD.
ALT net income for the last quarter is −24.64 M USD, while the quarter before that showed −24.39 M USD of net income which accounts for −1.01% change. Track more Altimmune, Inc. financial stats to get the full picture.
No, ALT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 13, 2024, the company has 59.00 employees. See our rating of the largest employees — is Altimmune, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Altimmune, Inc. EBITDA is −95.78 M USD, and current EBITDA margin is −19.49 K%. See more stats in Altimmune, Inc. financial statements.
Like other stocks, ALT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Altimmune, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Altimmune, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Altimmune, Inc. stock shows the buy signal. See more of Altimmune, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.